Mutation in NRAS in familial Noonan syndrome – case report and review of the literature

BMC Medical Genetics

Marie-Louise Bondeson²  Göran Annerén²  Otto Westphal⁴  Arie van Haeringen³  Eric Legius¹  Jovanna Dahlgren⁴  Maria Wilbe²  Sara Ekvall² 

[1] Department of Human Genetics, KU Leuven, Leuven, Belgium;Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, 751 85, Sweden;Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands;Department of Paediatrics, the Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden

关键词: RASopathies;    RAS-MAPK pathway;    Mutation;    Noonan syndrome;    NRAS;   

Others  :  1230637
DOI  :  10.1186/s12881-015-0239-1

 received in 2015-04-17, accepted in 2015-09-30,  发布年份 2015

【 摘 要 】

Background

Noonan syndrome (NS), a heterogeneous developmental disorder associated with variable clinical expression including short stature, congenital heart defect, unusual pectus deformity and typical facial features, is caused by activating mutations in genes involved in the RAS-MAPK signaling pathway.

Case presentation

Here, we present a clinical and molecular characterization of a small family with Noonan syndrome. Comprehensive mutation analysis of NF1, PTPN11, SOS1, CBL, BRAF, RAF1, SHOC2, MAP2K2, MAP2K1, SPRED1, NRAS, HRAS and KRAS was performed using targeted next-generation sequencing. The result revealed a recurrent mutation in NRAS, c.179G > A (p.G60E), in the index patient. This mutation was inherited from the index patient’s father, who also showed signs of NS.

Conclusions

We describe clinical features in this family and review the literature for genotype-phenotype correlations for NS patients with mutations in NRAS. Neither of affected individuals in this family presented with juvenile myelomonocytic leukemia (JMML), which together with previously published results suggest that the risk for NS individuals with a germline NRAS mutation developing JMML is not different from the proportion seen in other NS cases. Interestingly, 50 % of NS individuals with an NRAS mutation (including our family) present with lentigines and/or Café-au-lait spots. This demonstrates a predisposition to hyperpigmented lesions in NRAS-positive NS individuals. In addition, the affected father in our family presented with a hearing deficit since birth, which together with lentigines are two characteristics of NS with multiple lentigines (previously LEOPARD syndrome), supporting the difficulties in diagnosing individuals with RASopathies correctly. The clinical and genetic heterogeneity observed in RASopathies is a challenge for genetic testing. However, next-generation sequencing technology, which allows screening of a large number of genes simultaneously, will facilitate an early and accurate diagnosis of patients with RASopathies.

【 授权许可】

   
2015 Ekvall et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet. 2013; 381(9863):333-342.
• [2]Tartaglia M, Gelb BD. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci. 2010; 1214:99-121.
• [3]Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin Y, Tamburino AM, Neel BG et al.. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet. 2007; 39(1):70-74.
• [4]Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W et al.. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet. 2007; 39(1):75-79.
• [5]Martinelli S, Checquolo S, Consoli F, Stellacci E, Rossi C, Silvano M, Franciosa G, Flex E, Cossu C, De Luca A et al.. Loss of CBL E3-ligase activity in B-lineage childhood acute lymphoblastic leukaemia. Br J Haematol. 2012; 159(1):115-119.
• [6]Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Sakamoto KM, Gorr TA et al.. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. 2010; 42(9):794-800.
• [7]Perez B, Mechinaud F, Galambrun C, Ben Romdhane N, Isidor B, Philip N, Derain-Court J, Cassinat B, Lachenaud J, Kaltenbach S et al.. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. J Med Genet. 2010; 47(10):686-691.
• [8]Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, Scioletti AP, Esposito G, Cordeddu V, Lepri F et al.. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat. 2009; 30(4):695-702.
• [9]Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A et al.. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007; 39(8):1007-1012.
• [10]Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Amo R, Kamisago M, Momma K, Katayama H, Nakagawa M et al.. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet. 2007; 39(8):1013-1017.
• [11]Cordeddu V, Di Schiavi E, Pennacchio LA, Ma'ayan A, Sarkozy A, Fodale V, Cecchetti S, Cardinale A, Martin J, Schackwitz W et al.. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet. 2009; 41(9):1022-1026.
• [12]Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, Aoki Y, Matsubara Y, Arveiler B, Lacombe D et al.. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet. 2007; 44(12):763-771.
• [13]Aoki Y, Niihori T, Banjo T, Okamoto N, Mizuno S, Kurosawa K, Ogata T, Takada F, Yano M, Ando T et al.. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet. 2013; 93(1):173-180.
• [14]Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, Roberts AE, Lepri F, Merbitz-Zahradnik T, Konig R et al.. A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet. 2010; 42(1):27-29.
• [15]Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A, Digilio C, Palleschi A, Pizzuti A, Grammatico P et al.. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet. 2006; 79(1):129-135.
• [16]Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE et al.. Germline KRAS mutations cause Noonan syndrome. Nat Genet. 2006; 38(3):331-336.
• [17]Flex E, Jaiswal M, Pantaleoni F, Martinelli S, Strullu M, Fansa EK, Caye A, De Luca A, Lepri F, Dvorsky R et al.. Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. Hum Mol Genet. 2014; 23(16):4315-4327.
• [18]Allanson JE. Noonan syndrome. J Med Genet. 1987; 24(1):9-13.
• [19]van der Burgt I. Noonan syndrome. Orphanet J Rare Dis. 2007; 2:4. BioMed Central Full Text
• [20]De Filippi P, Zecca M, Lisini D, Rosti V, Cagioni C, Carlo-Stella C, Radi O, Veggiotti P, Mastronuzzi A, Acquaviva A et al.. Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia. Br J Haematol. 2009; 147(5):706-709.
• [21]Runtuwene V, van Eekelen M, Overvoorde J, Rehmann H, Yntema HG, Nillesen WM, van Haeringen A, van der Burgt I, Burgering B, den Hertog J. Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects. Dis Model Mech. 2011; 4(3):393-399.
• [22]Denayer E, Peeters H, Sevenants L, Derbent M, Fryns JP, Legius E. NRAS Mutations in Noonan Syndrome. Mol Syndromol. 2012; 3(1):34-38.
• [23]Kraoua L, Journel H, Bonnet P, Amiel J, Pouvreau N, Baumann C, Verloes A, Cave H. Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia. Am J Med Genet A. 2012; 158A(10):2407-2411.
• [24]Kratz CP, Franke L, Peters H, Kohlschmidt N, Kazmierczak B, Finckh U, Bier A, Eichhorn B, Blank C, Kraus C et al.. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. Br J Cancer. 2015; 112(8):1392-1397.
• [25]Strullu M, Caye A, Lachenaud J, Cassinat B, Gazal S, Fenneteau O, Pouvreau N, Pereira S, Baumann C, Contet A et al.. Juvenile myelomonocytic leukaemia and Noonan syndrome. J Med Genet. 2014; 51(10):689-697.
• [26]Noonan Syndrome.[http://www.ncbi.nlm.nih.gov/books/NBK1124/]
• [27]Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol. 2010; 1(1):2-26.